Skip to main content
. 2020 Jul 15;1(5):100062. doi: 10.1016/j.xcrm.2020.100062

Table 3.

Clinical and Demographic Data of 992 Tests in 913 Patients Who Had the SAMBA II SARS-CoV-2 Test in the Post-implementation Period

(N) Individual Patients = 913/Tests = 992
Male gender (%) n = 857/913
389 (44.6)
Median age, y (IQR) n = 909/913
63 (37–79)
Duration of illness, days (IQR) 2 (1–7)

SAMBA II SARS-CoV2 result (%)

 Positive 42 (4.2)
 Negative 950 (95.8)

Triage at initial assessment (%) n = 966/992

 Non-COVID-19 (green) 478 (49.5)
 Possible COVID-19 (amber) 387 (40.0)
 Likely COVID-19 (red) 101 (10.5)

Inpatient transfer (%) n = 976/992

 Yes 20 (2.0)
 No 956 (98.0)

Triage following SAMBA II SARS-CoV-2 result (%) n = 756/992

 Non-COVID-19 (green) 600 (79.4)
 Possible COVID-19 (amber) 88 (11.6)
 Likely COVID-19 (red) 68 (9.0)

Reason for SARS-CoV-2 test n = 970/992

 Admission triage and placement 580 (59.8)
 In-hospital triage and placement 94 (9.7)
 Discharge to nursing home/carers 97 (10.0)
 Pre-operative 110 (11.3)
 Facilitate other investigations 12 (1.2)
 Asymptomatic screening 37 (3.8)
 Other 40 (4.1)

Note that some individuals had multiple admissions each with associated POC tests. COVID-19, coronavirus disease 2019; IQR, interquartile range; POC, point of care; SAMBA, simple amplification-based assay; SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2.